A Phase II Study of ZT002 Injection With Subjects With Overweight or Obesity
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the percentage change from baseline in weight after 24 weeks of treatment with ZT002 Injection in subjects with overweight/obesity.